CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 9,437 enrolled
Drug / intervention
Role of EOSSother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03556059
NCT03556059N/ACompleted
CompareCT.gov

Procedure Selection in Obesity and Metabolic Surgery Based on the Edmonton Obesity Staging System (EOSS) - a Nationwide German Register-based Cohort Study (StuDoQ MBE)

Sana Klinikum Offenbach·interventional·Posted Jun 14, 2018·Updated Jan 24, 2019

In Brief

A clinical study evaluating Role of EOSS for Postoperative Complications. Completed, enrolled 9,437 participants across 1 site.

Detailed Summary

The Edmonton Obesity Staging System (EOSS) is a more comprehensive measure of obesity-related diseases and predictor of mortality than BMI or waist circumference. EOSS is also important in predicting post - operative outcome and 30-day mortality after metabolic surgery. The aim of this study is to determine whether EOSS could be an indicator for procedure selection in obesity and metabolic surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostoperative Complications
CountriesGermany
CollaboratorsDeutsche Gesellschaft für Allgemein- und Viszeralchirurgie

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 14, 2018
Enrollment StartFeb 1, 2015
Primary CompletionDec 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 8.0 years ago

Interventions

Role of EOSSother

The Edmonton Obesity Staging System (EOSS) is a more comprehensive measure of obesity-related diseases and predictor of mortality than body mass index (BMI) or waist circumference. Its application for the selection of obese patients for obesity surgery has been suggested. This study evaluates the role of the Edmonton Obesity Staging System (EOSS) in predicting postoperative outcome (next to the Clavien Dindo Classification) and 30-day mortality after metabolic surgery.